Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia.

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

April 26, 2019

Primary Completion Date

March 15, 2021

Study Completion Date

March 15, 2021

Conditions
Chronic Lymphocytic Leukemia
Interventions
COMBINATION_PRODUCT

PD-L1, PD-L2 peptides with Montanide ISA51

PD-L1: 19 amino acid sequence from the PD-L1 protein; PD-L2: 21 amino acid sequence from the PD-L2 protein; The peptides are dissolved in dimethyl sulphoxide (DMSO) and mixed with Montanide.

Trial Locations (1)

2730

Herlev Hospital, Herlev

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

IO Biotech

INDUSTRY

lead

Lars Møller Pedersen

OTHER

NCT03939234 - Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. | Biotech Hunter | Biotech Hunter